Current and Emerging Perspectives on Immunotherapy for Melanoma

Seminars in Oncology

Volumn 42, Issue , 2015, Pages S3-S11

  Daud, Adil ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOMODULATING AGENT; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER; MONOCLONAL ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COLITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPITUITARISM; HYPOTHYROIDISM; IMMUNE SYSTEM; MELANOMA; NEPHRITIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIGNAL TRANSDUCTION; THYROID DISEASE; TOXIC HEPATITIS; TUMOR IMMUNITY; UVEITIS; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION;

EID: 84947814362     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.10.003     Document Type: Review

References (39)

1. R.D. Schreiber, L.J. Old, and M.J. Smyth Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 2011 1565 1570
2. P. Sharma, and J.P. Allison The future of immune checkpoint therapy Science 348 2015 56 61
3. S.L. Topalian, C.G. Drake, and D.M. Pardoll Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell 27 2015 450 461
4. P. Sharma, and J.P. Allison Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential Cell 161 2015 205 214
5. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of anti-tumor immunity by CTLA-4 blockade Science 271 1996 1734 1736
6. A.A. Hurwitz, Y.u. TF-Y, D.R. Leach, and J.P. Allison CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma Proc Natl Acad Sci U S A 95 1998 10067 10071
7. A. van Elsas, A.A. Hurwitz, and J.P. Allison Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J Exp Med 190 1999 355 366
8. R. Waitz, M. Fassò, and J.P. Allison CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection Oncoimmunology 1 2012 544 546
9. D. Zamarin, R.B. Holmgaard, S.K. Subudhi, and et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy Sci Transl Med 6 2014 226ra32
10. Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J 11 1992 3887 3895
11. G.J. Freeman, A.J. Long, Y. Iwai, and et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
12. D.M. Pardoll Immunology beats cancer: a blueprint for successful translation Nat Immunol 13 2012 1129 1132
13. H. Dong, S.E. Strome, D.R. Salomao, and et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
14. J.M. Taube, R.A. Anders, G.D. Young, and et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127ra37
15. P.C. Tumeh, C.L. Harview, J.H. Yearley, and et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 2014 568 571
16. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr Opin Immunol 24 2012 207 212
17. F.S. Hodi, M. Butler, D.A. Oble, and et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients Proc Natl Acad Sci U S A 105 2008 3005 3010
18. B. Carthon, J.D. Wolchok, J. Yuan, and et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial Clin Cancer Res 16 2010 2861 2871
19. D.S. Chen, and I. Mellman Oncology meets immunology: the cancer immunity cycle Immunity 39 2013 1 10
20. A.J. Korman, K.S. Peggs, and J.P. Allison Checkpoint blockade in cancer immunotherapy Adv Immunol 90 2006 297 339
21. S. Topalian, M. Sznol, D. McDermott, and et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 2014 1020 1030
22. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
23. C. Robert, L. Thomas, I. Bondarenko, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
24. D.B. Johnson, C. Peng, and J.A. Sosman Nivolumab in melanoma: latest evidence and clinical potential Ther Adv Med Oncol 7 2015 97 106
25. M.A. Postow, M.F. Callahan, and J.D. Wolchok Immune checkpoint blockade in cancer therapy J Clin Oncol 33 2015 1974 1982
26. J.R. Brahmer, C.G. Drake, I. Wollner, and et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
27. S. Topalian, F.S. Hodi, J. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1antibody in cancer N Engl J Med 366 2012 2443 2454
28. A. Daud, A. Ribas, C. Robert, and et al. Long-term efficacy of pembrolizumab in a pooled analysis of 655 patients with advanced melanoma enrolled in KEYNOTE-001 [abstract] J Clin Oncol (Meeting Abstracts) 33 2015 9005
29. C. Robert, J. Schachter, G.V. Long, and et al. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2015 2521 2532
30. M.A. Postow, J. Chesney, A.C. Pavlick, and et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2015 2006 2017
31. C. Robert, A. Ribas, J.D. Wolchok, and et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial Lancet 384 2014 1109 1117
32. A. Ribas, S. Hodi, R. Kefford, and et al. Efficacy and safety of the anti-PD-1monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) [abstract] J Clin Oncol (Meeting Abstracts) 2014 32 LBA9000
33. Ribas A, Wolchok JD, Robert C, et al. Updated clinical efficacy of the anti-PD-1monoclonal antibody pembrolizumab (pembro, MK-3475) in 411 patients (pts) with melanoma (MEL). Presented at Society for Melanoma Research (SMR) 2014 International Congress; 2014 November 13-16; Zurich, Switzerland.
34. I. Puzanov, R. Dummer, J. Schachter, and et al. Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (MK-3475) versus chemotherapy in patients with ipilimumab-refractory advanced melanoma [abstract] J Clin Oncol (Meeting Abstracts) 33 2015 3012
35. C. Robert, G. Long, B. Brady, and et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 2015 320 330
36. J.S. Weber, S.P. D'Angelo, D. Minor, and et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Lancet Oncol 16 2015 375 384
37. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 2015 23 34
38. J.S. Weber, R.R. Kudchadkar, B. Yu, and et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naïve melanoma J Clin Oncol 31 2013 4311 4318
39. C. Robert, L. Min, A.M. Joshua, and et al. Immune-related thyroid disorders with pembrolizumab (MK-3475) in patients with advanced melanoma treated in KEYNOTE-001 [abstract] J Clin Oncol (Meeting Abstracts) 33 2015 9050